For people trying to conceive, the most important shift in the move from PCOS to polyendocrine metabolic ovarian syndrome is not the label itself but the recognition, highlighted by Dr Elias Tsakos, FRCOG, Medical Director of Embryoclinic, Greece, that this common condition reaches far beyond the ovaries and can shape fertility treatment, pregnancy risks, and long-term health.
For years, polycystic ovarian syndrome has been suggested to be a disorder centred on the ovaries. That framing was always too narrow. The ovaries still matter, but they are only one part of a broader condition that can involve endocrine disruption, abnormal insulin and metabolism, and wider cardiometabolic risk.
The new term, polyendocrine metabolic ovarian syndrome, is meant to reflect that reality. It points to a multisystem disorder rather than an isolated gynaecological problem. It also corrects one of the most misleading parts of the old name: the “cysts” are not pathological ovarian cysts, but abnormal follicles.
That distinction is more than semantic. Around 1 in 10 women are affected, and the old terminology was linked to confusion, stigma, and delayed diagnosis. When a condition is framed mainly as an ovarian issue, it is easier to miss the metabolic and cardiovascular risks that may be just as important as irregular periods or fertility problems.
The renaming followed a long international effort. The consensus was published in The Lancet on 05/12/2026 after more than 14 years of work across 6 continents, with more than 14,000 patients and professionals contributing, and 56 scientific organisations endorsed it. For patients, the practical message is simple: if you have been told you have PCOS, or suspect you do, your care should be broader than an ultrasound and a conversation about ovulation.
The core diagnostic framework remains the same. Diagnosis still requires two out of three features. Those features are:
That third point is one of the most patient-relevant updates. Instead of relying on pelvic ultrasound to identify polycystic ovarian morphology, serum AMH can now be used in the diagnostic pathway. This matters because ultrasound can be operator dependent, invasive when transvaginal, and difficult in younger patients or those who are not sexually active. It also depends on cost and access.
A blood test for AMH is simpler and more reproducible. It is operator-independent and easier to access through primary care. In practice, that could lower barriers to diagnosis and help more patients get assessed earlier, especially those who have symptoms but have struggled to get a clear answer.
For patients considering IVF, the biggest takeaway is that PMOS should not be treated as a side note. It can affect fertility directly and indirectly, and it can also influence how safely and effectively treatment proceeds.
That is true even in situations where some patients assume the diagnosis no longer matters. A woman pursuing IVF at 47 with donor eggs may think ovarian factors are no longer relevant, but the broader syndrome still is. PMOS is not only about egg supply. It is a multi-endocrine and metabolic condition that can affect treatment readiness, pregnancy health, and the risk of complications such as hypertension and diabetes. Those risks are already high at that age and become even more concerning if PMOS is unmanaged.
The same logic applies earlier in treatment. A poor IVF outcome may not be explained by age alone if an underlying metabolic problem has not been fully evaluated. In one discussion point, a patient with apparently reassuring first-line numbers turned out to have a more profound metabolic syndrome when testing went further. That kind of hidden risk matters because normal-weight patients and patients with only mildly abnormal routine results can still have significant metabolic dysfunction.
This is why IVF preparation in PMOS should not stop at counting follicles or checking whether periods are regular. A fuller assessment can change how a cycle is approached and whether it makes sense to optimise health first.
One of the most persistent misconceptions is that this syndrome is mainly a problem for people with obesity. Obesity is often present, but not always. Lean PMOS exists, and it can be missed because both patients and clinicians may underestimate risk when BMI is normal.
That matters in fertility care because normal-weight patients are often under-screened and under-treated. BMI should not be used as a filter for deciding who needs metabolic evaluation. A patient with a BMI of 20 can still have androgen excess, insulin resistance, blood sugar instability, and cardiovascular risk that deserves attention before embryo transfer or ovarian stimulation.
Symptoms can offer clues. Excess hair, acne, alopecia, acanthosis, sugar cravings, and blood sugar crashes may all point toward a broader metabolic problem, even when cycles are not dramatically irregular. A cycle pattern of 26 to 31 days does not automatically rule out a meaningful syndrome if other features are present.
For IVF patients, this is especially important because severe ovarian involvement can make stimulation difficult. Large numbers of follicles may sound reassuring at first glance, but they can come with management challenges. In severe cases, hormonal instability during stimulation may affect egg quality, and treatment planning becomes more complex.
If PMOS is suspected or already diagnosed, metabolic screening should be central to care. That applies across the weight spectrum, not only to patients with obesity. The goal is not simply to confirm a label but to identify the factors that could affect fertility treatment, pregnancy, and long-term health.
A thorough workup may include:
This broader approach reflects the new understanding of the syndrome. PMOS affects the reproductive, endocrine, and metabolic systems. It can also have a significant psychological impact, which should be addressed as part of care rather than treated as separate from the diagnosis.
That wider lens is one of the most meaningful changes for patients. The disease itself does not change overnight, and neither do medication plans or fertility protocols. What changes is the expectation that care should look beyond the ovaries and include mental health, cardiovascular risk, and metabolic status from the start.
A recurring problem in fertility care is false reassurance from limited screening. A patient may have a normal fasting blood sugar, an HbA1c of 5.7, and almost normal blood pressure, yet still have a more significant metabolic syndrome that affects ovarian response and egg quality. When IVF outcomes are disappointing, that hidden layer can become clinically important.
This is one reason the PMOS framework may help patients. It encourages doctors to diagnose, stratify, control, and manage the endocrine, metabolic, multi-organ, and mental aspects of the condition before moving ahead with treatment. That does not mean every patient needs the same intervention. It means the evaluation should be broad enough to catch what a narrow ovarian focus might miss.
For some patients, lifestyle counselling may be part of the plan. For others, medical or pharmaceutical treatment may be considered. Psychological interventions also belong in the conversation. The notes make clear that this is not a syndrome that can always be “fixed” with vitamins alone, particularly when there are clear signs of insulin resistance or severe ovarian involvement.
Replacing ultrasound with AMH in the diagnostic pathway may reduce one barrier, but it does not simplify the syndrome itself. PMOS is still highly individual. Some patients present mainly with irregular ovulation. Others are more affected by androgen symptoms such as acne and hirsutism. Others may have prominent metabolic features, psychological distress, or all of the above.
That is why a multidisciplinary team approach makes sense. Fertility treatment may be one part of the picture, but so are metabolic management, cardiovascular risk assessment, and mental health support. The new terminology pushes care in that direction by making the multisystem nature of the condition harder to ignore.
It also broadens the timeline. PMOS does not stop mattering once fertility treatment ends. The syndrome remains relevant after the reproductive years, including in climacteric, menopause, and post-menopause. Earlier identification and better support may help patients address symptoms sooner and reduce the risk of serious side effects later in life.
If you have a diagnosis of PCOS, or suspect you may have it, the practical question is not whether your chart says PCOS or PMOS. The practical question is whether your fertility care is looking at the whole syndrome.
Before IVF, it may be worth asking whether your evaluation has gone beyond ovarian appearance and cycle history. Have insulin resistance and diabetes risk been assessed if symptoms suggest a problem? Has cardiovascular risk been considered? If you are lean, has anyone assumed you are low risk based on BMI alone? If your previous cycle response was unexpectedly poor, has anyone looked for a deeper metabolic explanation?
In some cases, laboratory strategy may also matter. When embryo development is disappointing, discussion may include ICSI technique, sperm selection methods, blastocyst culture, time-lapse incubators, or PGT-A. But those decisions sit alongside, not instead of, a proper assessment of the underlying syndrome. Optimising metabolic status before another cycle may be just as important as changing the embryology plan.
The shift from PCOS to polyendocrine metabolic ovarian syndrome is really a shift in perspective. It asks patients and clinicians to stop treating a common condition as if it lives only in the ovaries and to recognise its reproductive, metabolic, cardiovascular, and psychological dimensions.
For IVF patients, that broader view can be useful rather than alarming. It creates more opportunities to identify hidden risks, tailor treatment, and improve the chances of a healthier pregnancy. The name may be new, but the most valuable message is straightforward: better diagnosis should lead to better preparation, and better preparation can shape far more than a single IVF cycle.
No. PMOS is not irrelevant at this age. It is a multi-endocrine and metabolic disease that affects fertility directly and indirectly, so it needs to be diagnosed, stratified, and managed.
This matters not only for IVF success, but also for the success of pregnancy and for a healthier pregnancy. At 47, whether pregnancy happens naturally or through IVF, the risks of common complications such as hypertension and diabetes are already very high, and they are even higher if PMOS is unmanaged.
Using your own eggs at this age is a challenge by itself, and it becomes an even greater challenge if PMOS is uncontrolled. Any modifiable factors should be optimised before treatment. A good example is a 41-year-old patient with a BMI of 32, normal fasting blood sugar, HbA1c of 5.7, and almost normal blood pressure who responded poorly to stimulation and produced half a dozen poor-quality eggs. Further testing showed a more profound metabolic syndrome than the initial tests suggested.
The right approach is to diagnose, stratify, control, and manage the endocrine, metabolic, multi-organ, and mental aspects before proceeding.
Fourteen fertilised eggs at age 41 probably point to hidden PCOS or PMOS, and this should be investigated thoroughly with hormonal testing, androgen testing, AMH, ultrasound assessment, and a full metabolic profile.
Before another IVF cycle, metabolic status should be optimised. Calcium activation is one possible approach, but there is not much evidence proving it is helpful.
A 13% blastocyst rate at age 41 is low, but not extremely low. Even one blastocyst in a woman over 40 is a good thing. Before a third attempt, it is worth looking closely at laboratory expertise and technique: who performs ICSI, how ICSI is done, and whether sperm selection techniques are used. Donor sperm alone does not guarantee a perfect sample.
PGTA should also be considered. Even if one or two blastocysts are created, they still need to be shown to be DNA competent before implantation.
This is a typical case of polyendocrine metabolic syndrome and a classic lean PCOS presentation. It is not something that can be fixed simply with vitamins.
The priority is to address insulin resistance, metabolic imbalances, hormonal imbalances, androgen excess, and cardiovascular risk. A full diagnosis, full metabolic checkup, cardiovascular risk assessment, and diabetes assessment are needed. When there are clinical manifestations of insulin resistance, medical treatment such as Glucophage or something similar should be considered.
An AMH of 52 picomoles and 40-plus follicles suggest severe syndrome. Massive ovaries can make stimulation difficult, and protocol management can be very challenging. Crashes of estrogens are not uncommon, especially between stimulation days 7, 8, and 10, and this can harm egg quality.
In severe syndrome, ovarian drilling is also worth considering, as it may help optimise both the metabolic and stimulation aspects.
Laboratory strategy matters as well. Useful options include sperm sorting techniques, selecting the best sperm, ICSI, time-lapse incubators, blast culture, and definitely PGTA. There is still reason to be optimistic, because 39 is still a reasonably good age and healthy, and DNA-normal blastocysts may still be identified.
Yes, and this shift matters because patients have been underserved when care focused only on polycystic-looking ovaries.
Too little attention has been given to metabolic issues, psychological issues, and risk. The syndrome does not stop mattering after the reproductive years. It remains relevant in climacteric, menopause, and after menopause.
Early identification makes a real difference. When women are recognised early, their challenges are acknowledged, their symptoms and features are addressed individually, and they are empowered with solutions, they are better equipped to prevent serious side effects of the syndrome later in life.
